Value of Ultrasound-Guided Microwave Ablation for Breast Fibroadenoma (mua)
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
상세 설명
Breast fibroadenomas are commonly seen among women worldwide, with the incidence having increased over the past few decades. The breast fibroadenoma arise due to proliferation of ductal or lobular tissue, and their treatment is controversial. Small asymptomatic breast lesions generally do not require treatment, and some surgeons tend to favor conservative management of breast fibroadenoma with regular follow-up, which should be accompanied by auxiliary examination (i.e., ultrasound and/or mammography and pathological assessment) every 3-6 months in order to dynamically monitor the status of breast lesions. However, some patients with large-sized breast fibroadenomas suffering from pain or anxiety are not satisfied with the conservative management approach and seek for treatment. Thus, it is necessary to excise part of the breast fibroadenoma according to therapeutic options that depend on different presenting situations Surgical resection is the most effective treatment option for patients suffering from breast lesions, although it is an invasive procedure. The patients much prefer a better cosmetic outcome and fewer surgically associated complications, which are commonly associated with minimally invasive procedures. Ultrasound-guided percutaneous microwave ablation (MWA) is a new minimally invasive treatment technology used in breast fibroadenoma and has emerged as a hot topic of clinical exploration in recent years. MWA has already shown promising results in treating liver carcinoma and pulmonary tumors, and in the settings of adrenal and renal malignancies Currently, in relation to benign lesions, MWA is considered a promising treatment option for patients with benign thyroid nodules given its advantage of being minimally invasive, scar-free, and relatively safe, and is associated with fewer post-operative complications.
To the best of our knowledge, MWA, as a thermal ablation technique, is increasingly being accepted by surgeons and clearly needs to be evaluated
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 해당 없음
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
설명
Inclusion criteria:
- Female participants ≥ 18 years
- Diagnosed with fibroadenoma by clinical and ultrasonographic signs, core needle biopsy done only if atypical fibroadenoma.
- Lesion(s) measurable by ultrasound (e.g., diameter 0.7 - 3.0 cm),distance from breast lesion to the skin and pectoralis muscle exceeding 10 mm and the lesion away from nipple areola area .
- Symptomatic lesion or patient preference for minimally invasive treatment
Exclusion criteria:
- Malignancy or high suspicion of malignancy, BIRADs 4 or more/if pathological proved.
- Active infection.
- Coagulopathy or contraindications to ablation.
- Distance from breast lesion to the skin and pectoralis muscle less than 10 mm and the lesion near nipple areola area .
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
다른: breast fibroadenoma
Fibroadenoma is a common benign breast lesion resulting from the excess proliferation of connective tissue.
Fibroadenomas characteristically contain both stromal and epithelial cells.
Fibroadenomas typically occur in women between the ages of 10 and 40 years.
It is the most common solid breast mass in women of all ages and the most common breast mass in the adolescent and young adult population..
The lesions are well-defined and well-circumscribed clinically, with normal overlying skin.
The lesions are not fixed to the surrounding parenchyma and slide around with palpation, hence the colloquial term a breast "mouse".
|
Patients will be positioned supine or lateri-cumbent, which fully exposed the breast and permitted surgical disinfection.
During the administration of a local anesthetic, the investigators will carefully administer a mixture of 2% lidocaine and 0.9% saline solution into the surrounding breast fibroadenoma to achieve a liquid isolated region to protect the skin, pectoralis, and areola from thermal injury.
Under real-time ultrasound guidance, an MWA antenna will be inserted into the breast fibroadenoma, and therapy will be ceased until the hyper echoic area completely cover the entire breast fibroadenoma
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
assess the efficacy of MWA in reducing fibroadenoma volume
기간: 12 months
|
Volume Reduction Ratio (VRR): Calculated to see how much the fibroadenoma has shrunk.
Measure 3 orthogonal diameter, calculate volume: L x W x H x0.5 and compare to previous exam.
|
12 months
|
|
To evaluate the safety profile of MWA (adverse events, complications).
기간: 18 months
|
the investigators will follow up the patients for any appearance of unwanted changes or any complications
|
18 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Cosmetic outcome - breast shape and symmetry
기간: 18 months
|
Assessment of breast shape and symmetry using the Breast Symmetry Scale (1-4), where 1 = excellent symmetry and 4 = marked deformity.
|
18 months
|
|
Cosmetic outcome - scar appearance
기간: 18 months
|
Assessment of skin scar quality using the Patient and Observer Scar Assessment Scale (POSAS) or Vancouver Scar Scale.
|
18 months
|
|
Cosmetic outcome - skin pigmentation changes
기간: 18 months
|
Assessment of hyperpigmentation or hypopigmentation at the ablation site compared to the contralateral breast, graded as: 0 = none, 1 = mild, 2 = moderate, 3 = severe.
|
18 months
|
|
Patient satisfaction
기간: 18 months
|
Assessment of patient satisfaction with the overall procedure and cosmetic results using a 5-point Likert scale.
|
18 months
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (추정된)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- breast fibroadenoma MWA
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .